CBG for depression and anxiety research showing cannabis leaf and brain wellness concept

CBG for Depression and Anxiety: What Research Really Shows

CBG for Depression and Anxiety has become a fascinating area of cannabinoid research. Even though THC and CBD have been the main focus of cannabinoid research so far, cannabigerol (CBG) has attracted researchers to examine the possibility that the less known cannabinoids can affect our mood and stress levels.

There is some promising scientific research, but there is a lot we do not know yet.

First studies performed on CBG showed its effect on some biological pathways which could be connected to mood and stress. Recently, some researchers have started testing cannabigerol on humans. According to the randomized, double-blind, placebo-controlled study conducted in 2024, a single dose of 20 mg of hemp-derived cannabigerol reduced anxiety and stress levels in healthy adult participants.

It is indeed exciting information but it does not confirm the use of CBG in treating depression and anxiety disorders.

Let us explore the findings of the scientists in more details.

What Is CBG?

CBG refers to cannabigerol, a cannabinoid that occurs naturally in the Cannabis sativa plant.

CBG is also referred to as a “minor cannabinoid” since there is usually much less of it compared to THC and CBD in cannabis plants.

CBG is additionally an intriguing compound since cannabigerolic acid (CBGA) is an earlier part of the cannabinoid biosynthesis pathway. CBGA may eventually be used in the production of other major cannabinoid acids such as THCA and CBDA.

Unlike THC, CBG is usually non-intoxicating, meaning that it does not provide the usual cannabis high that results from THC use.

That is one of the reasons why CBG is being researched for potential treatment of moods, stress, pain, inflammation, and nervous system conditions.

How CBG May Affect Mood and Stress

CBG does not seem to act through any one pathway.

Rather, there is evidence of its interactions with multiple receptor systems and pathways.

Laboratory studies indicate CBG can affect cannabinoid receptors, transient receptor potential (TRP) channels, α2-adrenergic receptors, and serotonin pathways. CBG may even interfere with anandamide signaling by inhibiting its reuptake.

This is relevant, as the mechanisms of stress and mood modulation are quite complicated.

As an illustration, CBG was found to be active at the α2-adrenergic receptor and 5-HT1A serotonin receptor in experimental studies. Those receptors are part of mechanisms associated with neurotransmission, stress reactions, and emotional control.

Nevertheless, just because a substance is active at a certain receptor in laboratory conditions does not necessarily mean that taking it will have an antidepressant or anxiolytic effects on humans.

Here comes the importance of human research.

CBG for Depression and Anxiety: Human Research

In terms of CBG for Depression and Anxiety, the most significant breakthrough is the development of studies involving humans under controlled conditions.

In 2024, scientists performed a double-blind, placebo-controlled crossover trial on 34 healthy participants.

They were given 20 mg of CBG extracted from hemp or a placebo during different sessions. They measured anxiety, stress, mood, memory, drug effect, and impairment.

The scientists claim that CBG provided more significant relief from anxiety and stress than the placebo did at some stages of the trial.

Verbal memory was better in those who were given CBG rather than the placebo. Scientists detected no signs of intoxication or impairment in the tests.

What Does It Mean?

This is promising—however, there is one significant limitation in the study.

These individuals were healthy volunteers, rather than those diagnosed with conditions such as generalized anxiety disorder, major depressive disorder, PTSD, or other psychiatric issues.

The research was also performed based on the acute effects of a single dosage of CBG, rather than the effects of long-term therapy.

Therefore, while these results imply that CBG requires further studies to prove its value in anxiety and stress relief, they do not mean that CBG will be used as a treatment of a mental health issue.

What About Depression?

There is much more evidence supporting the use of CBG for Depression and Anxiety than for depression.

While there have been preclinical studies suggesting the possible antidepressant-like effects, direct human studies have not proven yet the effectiveness of CBG as a depression treatment.

This is an essential factor.

A substance may affect certain processes within the body without producing any antidepressant effect in people with clinical depression.

In order to prove the antidepressant effects of CBG, large controlled trials including the subjects diagnosed with depression should be performed.

As for now, it is more correct to speak about CBG as an area of research rather than depression treatment.

CBG and the Endocannabinoid System

Endocannabinoid System (ECS)
The ECS consists of receptors, endocannabinoids produced naturally by the body, and enzymes that play a role in controlling various physiological functions.

These include:

Mood
Stress
Sleep
Pain
Appetite
Memory
Immune function

There seems to be a distinct difference between how CBG interacts with the ECS compared to THC.

Studies have found that CBG shows weaker interaction with the CB1 and CB2 receptors than THC, but that it has influence on other molecular targets as well.

A very intriguing target is anandamide.

CBG has been found to reduce the uptake of anandamide, meaning that more of this naturally occurring endocannabinoid can stay available.

The extent to which this influences CBG’s effect on mood and stress is still unclear.

How Does CBG Compare to CBD?

Both CBG and CBD are frequently paired, yet they are not the same compounds.

They are both thought to be non-intoxicating, yet they affect biological targets in different ways.

CBD has received significantly more research than CBG, especially in epilepsy and anxiety disorders.

CBG has considerably less research done on it clinically.

CBG is also an agonist of several other receptors that CBD does not act on.

This makes it inappropriate to state that CBG will have the same effects as CBD.

Rather, CBG is being researched as a compound distinct from CBD in its own right.

Is CBG Intoxicating?

CBG is normally regarded as being non-intoxicating.

This implies that it does not cause the potent psychoactive effects that are characteristic of THC.

The 2024 study of anxiety in humans showed that there were no signs of subjective effects or impairment after the administration of 20 mg of CBG.

It should be noted that “non-intoxicating” does not necessarily translate into “safe.”

Individuals can react differently to cannabinoids, while some products may have different formulations.

CBG Safety and Side Effects

One of the most significant shortcomings in cannabinoid research over time has always been the absence of any controlled human safety information.

But times have changed.

In a Phase 1 2026 study, oral CBG was given to 12 healthy volunteers at various single doses ranging from 25 mg to 200 mg. Pharmacokinetics, subjective effects, cognitive effects, physiological effects, adverse events, and liver function parameters were assessed.

There were no adverse events associated with the drug, and the liver-function parameters stayed in the normal range after the administration of the highest doses used in the study.

Nonetheless, chronic dosing studies are necessary for CBG.

And here is why: short-term tolerability does not imply long-term safety.

What the 2026 Safety Study Revealed

The 2026 study also indicated significant individual variability in CBG metabolism.

Pharmacokinetic modifications due to doses were noted; however, few pharmacodynamic alterations were noticed.

Feelings like being “jittery,” “active,” or “calm” were noticed in some individuals, whereas the highest dose led to an increase in appetite.

This information is quite helpful when assessing the mechanism of action of oral CBG in humans.

Is CBG an Alternative to Anxiety/Depression Medication?

It is important to realize at this stage that CBG cannot be considered as an alternative to existing treatments for depression or anxiety disorders.

Although the 2024 study appears promising, it included only 34 healthy participants who were subjected to acute effects of CBG.

It is also known that all preclinical studies do not have positive results.

For example, one rat study assessing oral CBG did not identify anxiolytic effect in one behavioral test, and did not conclude about its usefulness as an oral CBG therapy for anxiety and inflammatory pain.

It is always important to understand that cannabinoid research can be very complex.

The results may differ depending on species, dosage, formulation, the design of the study, and the disease itself.

What Researchers Still Need to Learn

For CBG for Depression and Anxiety to be considered an evidence-based treatment choice for depression and anxiety, further research is required.

Key research issues are:

Is CBG effective in treating individuals with anxiety disorders?
Can CBG help alleviate depressive symptoms?
What is the optimal dosing regime?
How long do the effects last?
Is the daily use of CBG safe?
Is there any interaction between CBG and antidepressant or anti-anxiety
medication?
Who will benefit from CBG?
Does CBG have different effects when used in combination with CBD or other cannabinoids?

Scientists also require more information on the quality of the product, its absorption and metabolism, as well as chronic exposure to it.

Frequently Asked Questions

Does CBG help with anxiety?

Initial findings from human studies are promising. In a 2024 controlled study, a 20 mg CBG dosage was shown to alleviate symptoms of anxiety and stress relative to a placebo in healthy adults. However, further human studies on CBG for anxiety disorders are required.

Is CBG good for depression?

CBG has been a subject of some attention owing to preclinical research into mood pathways, but there is not enough human data to support the claim that CBG can be used for treatment of depression.

Will CBG get me high?

CBG is believed to be non-intoxicating, and a 2024 controlled human study found no subjective effects or performance impairment caused by the tested CBG dose.

Is CBG safer than THC?

CBG doesn’t cause the same intoxicating effects as THC, but there is no long-term evidence that CBG is safer than THC overall. In a 2026 Phase 1 study, orally administered CBG was found to be well-tolerated in a small number of healthy adults after single dosages.

What CBG dosage for anxiety?

It is not possible to state a standard CBG dose for the treatment of anxiety disorder due to the lack of sufficient clinical evidence. The 2024 study used a dose of 20 mg, but it shouldn’t be generalized to all individuals.

Can I take CBG with antidepressants?

It is not possible to say that CBG is safe for the use with any antidepressant due to a lack of sufficient data. One should consult with their doctor before mixing CBG and antidepressants.

Conclusion

The research surrounding CBG and its effects on depression and anxiety is promising, although it is still in the initial stages of development.

The most substantial evidence to date comes from a 2024 study conducted among healthy volunteers, in which a 20 mg dose of CBG significantly decreased anxiety and stress when compared to the placebo group.

Additionally, in a 2026 Phase I study, it was demonstrated that single oral doses of CBG have been generally well tolerated among healthy individuals.

In conclusion, CBG looks promising; however, promising does not necessarily mean clinically proven.

Further human clinical trials involving individuals diagnosed with anxiety and depression are required in order to make CBG a viable treatment option.

For now, anyone interested in trying CBG should consult a doctor prior to using it, especially if he or she is currently using another treatment method.